Gilead Sciences (GILD) says it's submitted a New Drug Application to the FDA for marketing...


Gilead Sciences (GILD) says it's submitted a New Drug Application to the FDA for marketing approval of cobicistat, a boosting agent that increases blood levels of certain commercially available protease inhibitors to enable once-daily dosing. Cobicistat is also a component of the Quad once-daily single tablet regimen for HIV, which is currently under U.S. and European regulatory review.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs